Abstract: Disclosed are methods and compositions for treating cognitive impairment due to frontotemporal dementia caused by progranulin mutations. More specifically, the invention relates to antisense oligonucleotides (ASOs) and their administration to subjects to increase progranulin protein levels in brain tissue, to treat cognitive impairment due to frontotemporal dementia caused by progranulin mutations.

Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infection also are described.

Abstract: The present disclosure relates to identification of inhibitors of hepatitis and herpesvirus replication including compounds of the formula: wherein the variables are as defined herein. Also provided are methods of treatment using agents so identified.

Abstract: The present disclosure is directed to methods of treating Zika virus infections using selective estrogen receptor modulators (SERMs), such as Tamoxifen, or a compound selected from CALP-1, A7, PMA, Chelerythrine, PHTPP, Tariquidar or S-Equol.

Abstract: The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ???1 and/or ?5?1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ???3, ???5, ???6, ???8, and/or ?IIb?3.

Abstract: Described are compounds and methods useful in measuring membrane permeability and efflux transporter activity in bacteria, including multidrug resistance Gram negative bacteria.

Abstract: The present disclosure relates to a system for positioning a patient on a medical device. More specifically, the present disclosure relates to a system for aligning a patient's head, spine, and shoulders for providing radiation treatment to a head and neck area of the patient.

Abstract: Provided herein are methods of preparing a template nucleic acid for next-generation sequencing. The methods comprise performing primer extension using c7dGTP instead of dGTP, which then allows for the input nucleic acids to be selectively digested by c7dGTP-resistant restriction enzymes, thereby enriching the template nucleic acid prior to next-generation sequencing library preparation.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins and their use as blood anticoagulants and for treating sepsis.

Abstract: Disclosed are fluidic devices and methods for preparing fluidic devices. More particularly, disclosed are fluidic devices having fiber scaffolds and methods for their preparation. Also disclosed are methods for culturing cells using the fluidic devices having fiber scaffolds.

Abstract: Compositions and methods for delivering enzymes in enzyme hydrogel formulations are disclosed. More particularly, the present disclosure relates to injectable enzyme hydrogel formulations and delivery of injectable enzyme hydrogel formulations. Also disclosed are methods for GALNS enzyme replacement therapy and lysosomal enzyme replacement therapy.

Abstract: Methods of determining an immune status of a subject are provided. Specifically, methods for determining whether a subject has been exposed to an immunogenic antigen are provided as well as methods for determining efficacy of a vaccine are described.

Abstract: In one aspect, the present disclosure provides a compound of the formula: In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Described are glutathione adducts of fatty aldehydes (FALD-GSH) and methods useful in the detection of FALD-GSH in the identification of pathologies associated with leukocyte-mediated disease conditions, including eosinophil and neutrophil activation. Thus, the present disclosure provides methods of diagnosing a subject as having or being at risk of developing a leukocyte-mediated disease (LMD) comprising (a) detecting the level of glutathione adducts of 2-halofatty aldehydes (FALD-GSH) in a sample; (b) comparing the amount of FALD-GSH with a control or standard reflective of diseased and/or healthy levels of FALD-GSH; and (c) diagnosing the subject as having or being at risk of developing LMD if the level of FALD-GSH in the sample is higher than the control or standard.

Abstract: The present disclosure provides compounds of the formula (I), (II), (III), wherein the variables are as defined herein for use in the treatment of fungal infections. In some embodiments, the fungal infection is an infection of Cryptococcus neojormans fungus. Also provided herein are compositions comprising a compound of formula I, II, or III and a second anti-fungal agent.

Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.

Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.

Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.

Abstract: Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.

Abstract: The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.